Pharmaceutical Research

, Volume 14, Issue 4, pp 546–549 | Cite as

Comparative Pharmacokinetics and Pharmacodynamics of Two Recomhinant Human Interferon Beta-la (IFNβ-la) Products Administered Intramuscularly in Healthy Male and Female Volunteers

  • John Alam
  • Susan Goelz
  • Patrice Rioux
  • James Scaramucci
  • Wendy Jones
  • Arthur McAllister
  • Marilyn Campion
  • Mark Rogge
Note
Avonex Rebif® interferon-beta-la pharmacokinetics pharmacodynamics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Baron S., Tyring S. K., Fleischmann, H. G., Coppenhaver W. R., Niesel D. H., Limpel D. W., Stanton G. J., and Hughes T. K. JAMA 266:1375–1383 (1991).Google Scholar
  2. 2.
    Alam J. Curr Op Biotech 6:688–691 (1995).Google Scholar
  3. 3.
    Jacobs L, et.al. Ann Neur 39:285–294 (1996).Google Scholar
  4. 4.
    Alam J., Gorman B., Stannard M., Dawson A., Loynds P., Mant T., and Fox, I. J Interferon Res 11(suppl 1):S246 (1991).Google Scholar
  5. 5.
    AVONEX U.S. Package Insert.Google Scholar
  6. 6.
    Palimisano L., Salmon P., Cotonnec J. Y., Samra H., and Klasen E. J Interferon & Cytokine Res 10(Suppl 1):S125 (1990).Google Scholar
  7. 7.
    Salmon P., Le Cotonnec J-Y., Galazka A., Abdul-Ahad A., Darragh A., J Interferon & Cytokine Res 16:759–764 (1996).Google Scholar
  8. 8.
    Fuchs D., Weiss G., Reibnegger G., Wachter H., Crit Rev Clin Lab Sci 29:307–341 (1992).Google Scholar
  9. 9.
    Witt P. L., Storer B. E., Bryan G. T., Brown R. R., Flashner M., Larocca A. T., Colby C. B., and Borden E. C. J Immunotherapy 13:191–200 (1993).Google Scholar
  10. 10.
    Chiang J., Gloff C., Yoshizawa C., and Williams G. Pharm Res 10:567–57 (1993).Google Scholar
  11. 11.
    Chiang J., Gloff C. A., Soike K., and Williams G. J Interferon Res 13:111–120 (1993).Google Scholar
  12. 12.
    WHO Expert Committee of Biological Standardization. 38th World Health Organization Technical Report, Series 771, p. 36–38 (1988).Google Scholar
  13. 13.
    Kenward M and Jones B. Design and Analysis of Cross-Over Trials. Chapman and Hall, 1989.Google Scholar
  14. 14.
    Canosi U., Macia M., Gazza L., Serlupi-Crescenzi O., Donini S., Antonetti F., and Galli G. J Immunol Methods 199:69–76 (1996).Google Scholar
  15. 15.
    Liberati A., Horisberger M., Palmisano L., Astolfi S., Nastari A., Mechati S., Villa A., Mancini S., Arzano S., Grignani F. J Interferon Res 12:329–336 (1992).Google Scholar
  16. 16.
    Liberati A. M., Garofani P., De Angelis V., Clemente F. D., Horisberger M., Cecchini M., Betti A. R., Palmisano L., Astolfi S., Nastari A., Villa A., Villa A., and Arzano S. J Interferon Res 14:61–69 (1994).Google Scholar
  17. 17.
    Paulesu L., Pessina G. P., and Bocci V. Proc Soc Exp Bio Med 200:414–417 (1992).Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • John Alam
    • 1
  • Susan Goelz
    • 2
  • Patrice Rioux
    • 3
  • James Scaramucci
    • 1
  • Wendy Jones
    • 4
  • Arthur McAllister
    • 1
  • Marilyn Campion
    • 1
  • Mark Rogge
    • 5
  1. 1.Medical AffairsBiogen, Inc, Fourteen Cambridge CenterCambridge
  2. 2.Cellular BiochemistryBiogen, Inc, Fourteen Cambridge CenterCambridge
  3. 3.Medical AffairsBiogen, EuropeNanterre CedexFrance
  4. 4.Bioassay, Biogen, Inc, Fourteen Cambridge CenterCambridge
  5. 5.Preclinical Development, Biogen, Inc, Fourteen Cambridge CenterCambridge

Personalised recommendations